MURA (Mural Oncology) Equity-to-Asset : 0.86 (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Mural Oncology Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Mural Oncology's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $174.14 Mil. Mural Oncology's Total Assets for the quarter that ended in Sep. 2024 was $203.27 Mil.

The historical rank and industry rank for Mural Oncology's Equity-to-Asset or its related term are showing as below:

MURA' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.64 Med: 0.86 Max: 0.95
Current: 0.86

During the past 3 years, the highest Equity to Asset Ratio of Mural Oncology was 0.95. The lowest was -0.64. And the median was 0.86.

MURA's Equity-to-Asset is ranked better than
77.05% of 1512 companies
in the Biotechnology industry
Industry Median: 0.67 vs MURA: 0.86

Mural Oncology Equity-to-Asset Historical Data

The historical data trend for Mural Oncology's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mural Oncology Equity-to-Asset Chart

Mural Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Equity-to-Asset

-0.51

-0.64

0.87

Mural Oncology Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Equity-to-Asset	Get a 7-Day Free Trial						-0.23	0.87	0.89	0.87	0.86

Competitive Comparison of Mural Oncology's Equity-to-Asset

For the Biotechnology subindustry, Mural Oncology's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mural Oncology's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mural Oncology's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Mural Oncology's Equity-to-Asset falls into.

Mural Oncology Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Mural Oncology's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	263.817	/	301.745
	=

Mural Oncology's Equity to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

Equity to Asset (Q: Sep. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	174.141	/	203.274
	=

Mural Oncology (NAS:MURA) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Mural Oncology Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Mural Oncology's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Mural Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mural Oncology PLC (NAS:MURA) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380

Website

https://www.muraloncology.com

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.